<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376591</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2516-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Access microbiology</Title><ISOAbbreviation>Access Microbiol</ISOAbbreviation></Journal><ArticleTitle>Genetic diversity and genomic epidemiology of SARS-CoV-2 during the first 3 years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">000853.v4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1099/acmi.0.000853.v4</ELocationID><Abstract><AbstractText>During the 3 years following the emergence of the COVID-19 pandemic, the African continent, like other regions of the world, was substantially impacted by COVID-19. In Morocco, the COVID-19 pandemic has been marked by the emergence and spread of several SARS-CoV-2 variants, leading to a substantial increase in the incidence of infections and deaths. Nevertheless, the comprehensive understanding of the genetic diversity, evolution, and epidemiology of several viral lineages remained limited in Morocco. This study sought to deepen the understanding of the genomic epidemiology of SARS-CoV-2 through a retrospective analysis. The main objective of this study was to analyse the genetic diversity of SARS-CoV-2 and identify distinct lineages, as well as assess their evolution during the pandemic in Morocco, using genomic epidemiology approaches. Furthermore, several key mutations in the functional proteins across different viral lineages were highlighted along with an analysis of the genetic relationships amongst these strains to better understand their evolutionary pathways. A total of 2274 genomic sequences of SARS-CoV-2 isolated in Morocco during the period of 2020 to 2023, were extracted from the GISAID EpiCoV database and subjected to analysis. Lineages and clades were classified according to the nomenclature of GISAID, Nextstrain, and Pangolin. The study was conducted and reported in accordance with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. An exhaustive analysis of 2274 genomic sequences led to the identification of 157 PANGO lineages, including notable lineages such as B.1, B.1.1, B.1.528, and B.1.177, as well as variants such as B.1.1.7, B.1.621, B.1.525, B.1.351, B.1.617.1, B.1.617.2, and its notable sublineages AY.33, AY.72, AY.112, AY.121 that evolved over time before being supplanted by Omicron in December 2021. Among the 2274 sequences analysed, Omicron and its subvariants had a prevalence of 59.5%. The most predominant clades were 21K, 21L, and 22B, which are respectively related phylogenetically to BA.1, BA.2, and BA.5. In June 2022, Morocco rapidly observed a recrudescence of cases of infection, with the emergence and concurrent coexistence of subvariants from clade 22B such as BA.5.2.20, BA.5, BA.5.1, BA.5.2.1, and BF.5, supplanting the subvariants BA.1 (clade display 21K) and BA.2 (clade display 21L), which became marginal. However, XBB (clade 22F) and its progeny such XBB.1.5(23A), XBB.1.16(23B), CH.1.1(23C), XBB.1.9(23D), XBB.2.3(23E), EG.5.1(23F), and XBB.1.5.70(23G) have evolved sporadically. Furthermore, several notable mutations, such as H69del/V70del, G142D, K417N, T478K, E484K, E484A, L452R, F486P, N501Y, Q613H, D614G, and P681H/R, have been identified. Some of these SARS-CoV-2 mutations are known to be involved in increasing transmissibility, virulence, and antibody escape. This study has identified several distinct lineages and mutations involved in the genetic diversity of Moroccan isolates, as well as the analysis of their evolutionary trends. These findings provide a robust basis for better understanding the distinct mutations and their roles in the variation of transmissibility, pathogenicity, and antigenicity (immune evasion/reinfection). Furthermore, the noteworthy number of distinct lineages identified in Morocco highlights the importance of maintaining continuous surveillance of COVID-19. Moreover, expanding vaccination coverage would also help protect patients against more severe clinical disease.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Djorwé</LastName><ForeName>Soulandi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco), Avenue Cdt Driss El Harti, PB 7955 Sidi Othman, Casablanca, Morocco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bourgogne Laboratory of Medical and Scientific Analysis, 136, residence belhcen, Bd Bourgogne, Casablanca, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malki</LastName><ForeName>Abderrahim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco), Avenue Cdt Driss El Harti, PB 7955 Sidi Othman, Casablanca, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nzoyikorera</LastName><ForeName>Néhémie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Higher Institute of Biosciences and Biotechnology, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Microbial Biotechnology and Infectiology Research, Mohammed VI Center for Research &amp; Innovation, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyandwi</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Département de Médecine, Faculté de Médecine, Université du Burundi, Bujumbura, Burundi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministère de la Santé Publique et de la Lutte contre le Sida, Institut National de Santé Publique de Bujumbura, Bujumbura, Burundi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zebsoubo</LastName><ForeName>Samuel Privat</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>School of Advanced Studies in Biotechnology and Private Health (EHEB), 183 Bd de la Resistance, Casablanca 20250, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellamine</LastName><ForeName>Kawthar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bourgogne Laboratory of Medical and Scientific Analysis, 136, residence belhcen, Bd Bourgogne, Casablanca, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bousfiha</LastName><ForeName>Amale</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco), Avenue Cdt Driss El Harti, PB 7955 Sidi Othman, Casablanca, Morocco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.25748970.v1</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Access Microbiol</MedlineTA><NlmUniqueID>101746927</NlmUniqueID><ISSNLinking>2516-8290</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">genetic diversity</Keyword><Keyword MajorTopicYN="N">genomic sequence</Keyword><Keyword MajorTopicYN="N">lineage</Keyword><Keyword MajorTopicYN="N">omicron</Keyword><Keyword MajorTopicYN="N">variant</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376591</ArticleId><ArticleId IdType="pmc">PMC11457919</ArticleId><ArticleId IdType="doi">10.1099/acmi.0.000853.v4</ArticleId><ArticleId IdType="pii">000853.v4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Djorwe S, Malki A, Nzoyikorera N, Nyandwi J, Zebsoubo SP, et al. Genetic diversity and genomic epidemiology of SARS-cov-2 during the first three years of the pandemic in Morocco: comprehensive sequence analysis, including the unique lineage B.1.528 in Morocco. figshare. 2024</Citation></Reference><Reference><Citation>Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health. 2022;22:1584. doi: 10.1186/s12889-022-14016-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14016-9</ArticleId><ArticleId IdType="pmc">PMC9392069</ArticleId><ArticleId IdType="pubmed">35987605</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Weekly epidemiological update on COVID-19. 2019.  [10-August-2023]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2023 accessed.</Citation></Reference><Reference><Citation>Najimi N, Tajount L, Regragui Z, Remz C, Ait-Lhaj-Mhand R, et al. Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers. Int J Immunopathol Pharmacol. 2024;38:3946320241260633. doi: 10.1177/03946320241260633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03946320241260633</ArticleId><ArticleId IdType="pmc">PMC11155355</ArticleId><ArticleId IdType="pubmed">38836458</ArticleId></ArticleIdList></Reference><Reference><Citation>Voskarides K. SARS-CoV-2: tracing the origin, tracking the evolution. BMC Med Genom. 2022;15:62. doi: 10.1186/s12920-022-01208-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-022-01208-w</ArticleId><ArticleId IdType="pmc">PMC8931788</ArticleId><ArticleId IdType="pubmed">35303887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, Li J, Gao W, Li Z, Zhang W. Multiple E3 ligases act as antiviral factors against SARS-CoV-2 via inducing the ubiquitination and degradation of ORF9b. J Virol. 2024;98:e0162423. doi: 10.1128/jvi.01624-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01624-23</ArticleId><ArticleId IdType="pmc">PMC11237466</ArticleId><ArticleId IdType="pubmed">38709105</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qaaneh AM, Alshammari T, Aldahhan R, Aldossary H, Alkhalifah ZA, et al. Genome composition and genetic characterization of SARS-CoV-2. Saudi J Biol Sci. 2021;28:1978–1989. doi: 10.1016/j.sjbs.2020.12.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2020.12.053</ArticleId><ArticleId IdType="pmc">PMC7834485</ArticleId><ArticleId IdType="pubmed">33519278</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94:1738–1744. doi: 10.1002/jmv.27524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27524</ArticleId><ArticleId IdType="pubmed">34905235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouikha A, Fares W, Laamari A, Haddad-Boubaker S, Belaiba Z, et al. Molecular epidemiology of SARS-CoV-2 in Tunisia (North Africa) through several successive waves of COVID-19. Viruses. 2022;14:624. doi: 10.3390/v14030624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030624</ArticleId><ArticleId IdType="pmc">PMC8956073</ArticleId><ArticleId IdType="pubmed">35337031</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457. doi: 10.1016/S0140-6736(07)61602-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare S, Gurry C, Freitas L, Schultz MB, Bach G, et al. GISAID’s role in pandemic response. China CDC Wkly. 2021;3:1049–1051. doi: 10.46234/ccdcw2021.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.255</ArticleId><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5:1403–1407. doi: 10.1038/s41564-020-0770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Toole Á, Scher E, Underwood A, Jackson B, Hill V, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021;7:veab064. doi: 10.1093/ve/veab064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veab064</ArticleId><ArticleId IdType="pmc">PMC8344591</ArticleId><ArticleId IdType="pubmed">34527285</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation calling and quality control for viral genomes. JOSS. 2021;6:3773. doi: 10.21105/joss.03773.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.03773</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes JD, Hinrichs AS, Clawson H, Gonzalez JN, Lee BT, et al. The UCSC SARS-CoV-2 genome browser. Nat Genet . 2020;52:991–998. doi: 10.1038/s41588-020-0700-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-0700-8</ArticleId><ArticleId IdType="pmc">PMC8016453</ArticleId><ArticleId IdType="pubmed">32908258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 2020;11:1800. doi: 10.3389/fmicb.2020.01800.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01800</ArticleId><ArticleId IdType="pmc">PMC7387429</ArticleId><ArticleId IdType="pubmed">32793182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lina B. Les différentes phases de l’évolution moléculaire et antigénique des virus SARS-CoV-2 au cours des 20 mois suivant son émergence. Bulletin de l’Académie Nationale de Médecine. 2022;206:87–99. doi: 10.1016/j.banm.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.banm.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8629187</ArticleId><ArticleId IdType="pubmed">34866635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Guo Y, Iketani S, Nair MS, Li Z, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh N, Nandi S, Saha I. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. Int Immunopharmacol. 2022;105:108565. doi: 10.1016/j.intimp.2022.108565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108565</ArticleId><ArticleId IdType="pmc">PMC8799522</ArticleId><ArticleId IdType="pubmed">35123183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazario-Toole AE, Xia H, Gibbons TF. Whole-genome sequencing of SARS-CoV-2: using phylogeny and structural modeling to contextualize local viral evolution. Mil Med. 2022;187:e130–e137. doi: 10.1093/milmed/usab031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/milmed/usab031</ArticleId><ArticleId IdType="pmc">PMC7928784</ArticleId><ArticleId IdType="pubmed">33609027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonçalves RL, Leite TCR, Dias B de P, Caetano CC da S, de Souza ACG, et al. SARS-CoV-2 mutations and where to find them: an in silico perspective of structural changes and antigenicity of the spike protein. J Biomol Struct Dyn. 2022;40:3336–3346. doi: 10.1080/07391102.2020.1844052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1844052</ArticleId><ArticleId IdType="pubmed">33155530</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wu J, Nie J, Zhang L, Hao H, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–1294. doi: 10.1016/j.cell.2020.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.012</ArticleId><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Odongo S, Okella H, Ndekezi C, Okee M, Namayanja M, et al. Towards refinement of COVID-19 disease vaccines, diagnostics, and therapeutics. PLoS One. 2021;17:e0279428. doi: 10.1371/journal.pone.0279428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0279428</ArticleId><ArticleId IdType="pmc">PMC9778641</ArticleId><ArticleId IdType="pubmed">36548384</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi H, Wang J, Wang J, Lu Y, Zhang Y, et al. The emergence and spread of novel SARS-CoV-2 variants. Front Public Health. 2021;9:696664. doi: 10.3389/fpubh.2021.696664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.696664</ArticleId><ArticleId IdType="pmc">PMC8364952</ArticleId><ArticleId IdType="pubmed">34409009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet . 2021;22:757–773. doi: 10.1038/s41576-021-00408-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00408-x</ArticleId><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzaoui Z, Ferjani S, Medini I, Charaa L, Landolsi I, et al. Genomic surveillance of SARS-CoV-2 in North Africa: 4 years of GISAID data sharing. IJID Reg . 2024;11:100356. doi: 10.1016/j.ijregi.2024.100356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijregi.2024.100356</ArticleId><ArticleId IdType="pmc">PMC11035039</ArticleId><ArticleId IdType="pubmed">38655560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–2361. doi: 10.1016/j.cell.2021.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.037</ArticleId><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta) Clin Infect Dis. 2022;75:e1128–e1136. doi: 10.1093/cid/ciab721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab721</ArticleId><ArticleId IdType="pmc">PMC8522361</ArticleId><ArticleId IdType="pubmed">34423834</ArticleId></ArticleIdList></Reference><Reference><Citation>Basheer A, Zahoor I. Genomic epidemiology of SARS-CoV-2 divulge B.1, B.1.36, and B.1.1.7 as the most dominant lineages in first, second, and third wave of SARS-CoV-2 infections in Pakistan. Microorganisms. 2021;9:2609. doi: 10.3390/microorganisms9122609.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9122609</ArticleId><ArticleId IdType="pmc">PMC8708969</ArticleId><ArticleId IdType="pubmed">34946210</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA, et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021;95:105038. doi: 10.1016/j.meegid.2021.105038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.105038</ArticleId><ArticleId IdType="pmc">PMC8364171</ArticleId><ArticleId IdType="pubmed">34403832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee D, Tauzin A, Laumaea A, Gong SY, Bo Y, et al. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses . 2022;14:144. doi: 10.3390/v14010144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010144</ArticleId><ArticleId IdType="pmc">PMC8780535</ArticleId><ArticleId IdType="pubmed">35062348</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184:2332–2347. doi: 10.1016/j.cell.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, Iketani S, Luo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature . 2021;593:130–135. doi: 10.1038/s41586-021-03398-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29:819–833. doi: 10.1016/j.chom.2021.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Morang’a CM, Ngoi JM, Gyamfi J, Amuzu DSY, Nuertey BD, et al. Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021. Nat Commun. 2022;13:2494. doi: 10.1038/s41467-022-30219-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30219-5</ArticleId><ArticleId IdType="pmc">PMC9076825</ArticleId><ArticleId IdType="pubmed">35523782</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature . 2021;596:276–280. doi: 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhatib M, Svicher V, Salpini R, Ambrosio FA, Bellocchi MC, et al. SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021. Microbiol Spectr. 2021;9:e0109621. doi: 10.1128/Spectrum.01096-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01096-21</ArticleId><ArticleId IdType="pmc">PMC8597642</ArticleId><ArticleId IdType="pubmed">34787497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemlali M, Chouati T, Ghammaz H, Melloul M, Alaoui Amine S, et al. Coding-complete genome sequences of a delta subvariant (AY.33) of SARS-CoV-2 obtained from Moroccan COVID-19 patients. Microbiol Resour Announc . 2022;11:e0109921. doi: 10.1128/mra.01099-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mra.01099-21</ArticleId><ArticleId IdType="pmc">PMC8812311</ArticleId><ArticleId IdType="pubmed">35112895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahni C, Chowdhury PBR, Devadas D, Ashish A, Singh NK, et al.   Cureus; 2022.  [15-February-2024]. SARS-CoV-2 mutations responsible for immune evasion leading to breakthrough infection.https://www.cureus.com/articles/114827-sars-cov-2-mutations-responsible-for-immune-evasion-leading-to-breakthrough-infection accessed.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9592688</ArticleId><ArticleId IdType="pubmed">36312656</ArticleId></ArticleIdList></Reference><Reference><Citation>Balupuri A, Kim J-M, Choi K-E, No JS, Kim I-H, et al. Comparative computational analysis of spike protein structural stability in SARS-CoV-2 Omicron subvariants. Int J Mol Sci . 2023;24:16069. doi: 10.3390/ijms242216069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242216069</ArticleId><ArticleId IdType="pmc">PMC10671153</ArticleId><ArticleId IdType="pubmed">38003257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol . 2022;32:e2381. doi: 10.1002/rmv.2381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2381</ArticleId><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Collier A-RY, Rowe M, Mardas F, Ventura JD, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med. 2022;386:1579–1580. doi: 10.1056/NEJMc2201849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2201849</ArticleId><ArticleId IdType="pmc">PMC9006770</ArticleId><ArticleId IdType="pubmed">35294809</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S-H, Chen Y-T, Lin X-Y, Ly Y-Y, Lien S-T, et al. In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design. Sci Rep. 2023;13:13468. doi: 10.1038/s41598-023-40741-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-40741-1</ArticleId><ArticleId IdType="pmc">PMC10439115</ArticleId><ArticleId IdType="pubmed">37596329</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib MT, Rahman S, Afrad MH, Howlader AM, Khan MH, et al. Natural selection shapes the evolution of SARS-CoV-2 Omicron in Bangladesh. Front Genet. 2023;14:1220906. doi: 10.3389/fgene.2023.1220906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2023.1220906</ArticleId><ArticleId IdType="pmc">PMC10446972</ArticleId><ArticleId IdType="pubmed">37621704</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur S, Sasi S, Pillai SG, Nag A, Shukla D, et al. SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines. Front Med. 2022;9:815389. doi: 10.3389/fmed.2022.815389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.815389</ArticleId><ArticleId IdType="pmc">PMC8902153</ArticleId><ArticleId IdType="pubmed">35273977</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol . 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, Song W, Xiao T, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature . 2022;608:593–602. doi: 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar A, Omar S, Alshareef A, Fanous K, Sarker S, et al. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum Vaccin Immunother. 2023;19:2212568. doi: 10.1080/21645515.2023.2212568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2212568</ArticleId><ArticleId IdType="pmc">PMC10234134</ArticleId><ArticleId IdType="pubmed">37254497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023;14:2800. doi: 10.1038/s41467-023-38435-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38435-3</ArticleId><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat Commun. 2023;14:2671. doi: 10.1038/s41467-023-38188-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38188-z</ArticleId><ArticleId IdType="pmc">PMC10175283</ArticleId><ArticleId IdType="pubmed">37169744</ArticleId></ArticleIdList></Reference><Reference><Citation>Makowski EK, Schardt JS, Smith MD, Tessier PM. Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. PLoS Comput Biol. 2022;18:e1010160. doi: 10.1371/journal.pcbi.1010160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1010160</ArticleId><ArticleId IdType="pmc">PMC9223403</ArticleId><ArticleId IdType="pubmed">35639784</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar Ticona JP, Xiao M, Li D, Nery N, Jr, Hitchings M, et al. Extensive transmission of SARS-CoV-2 BQ.1* variant in A population with high levels of hybrid immunity: a prevalence survey. Int J Infect Dis. 2024;139:159–167. doi: 10.1016/j.ijid.2023.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.11.039</ArticleId><ArticleId IdType="pmc">PMC10784150</ArticleId><ArticleId IdType="pubmed">38070701</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Li J, Pei S, Lu Y, Li C, et al. An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants. Front Cell Infect Microbiol. 2023;13:1297078. doi: 10.3389/fcimb.2023.1297078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1297078</ArticleId><ArticleId IdType="pmc">PMC10752979</ArticleId><ArticleId IdType="pubmed">38156316</ArticleId></ArticleIdList></Reference><Reference><Citation>Giancotti R, Lomoio U, Puccio B, Tradigo G, Vizza P, et al. The Omicron XBB.1 variant and its descendants: genomic mutations, rapid dissemination and notable characteristics. Biology. 2024;13:90. doi: 10.3390/biology13020090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology13020090</ArticleId><ArticleId IdType="pmc">PMC10886209</ArticleId><ArticleId IdType="pubmed">38392308</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Tracking SARS-CoV-2 variants. 2024.  [8-March-2024]. https://www.who.int/activities/tracking-SARS-CoV-2-variants accessed.</Citation></Reference><Reference><Citation>Cobar O, Cobar S.  Med Res Arch; 2023.  [1-April-2024]. XBB.2.3, prevalence, structural, genomic, and pathogenic properties.https://esmed.org/MRA/mra/article/view/4137 accessed.</Citation></Reference><Reference><Citation>Wu H, Xing N, Meng K, Fu B, Xue W, et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe. 2021;29:1788–1801. doi: 10.1016/j.chom.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.11.005</ArticleId><ArticleId IdType="pmc">PMC8590493</ArticleId><ArticleId IdType="pubmed">34822776</ArticleId></ArticleIdList></Reference><Reference><Citation>Muradyan N, Arakelov V, Sargsyan A, Paronyan A, Arakelov G, et al. Impact of mutations on the stability of SARS-CoV-2 nucleocapsid protein structure. Sci Rep. 2024;14:5870. doi: 10.1038/s41598-024-55157-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55157-8</ArticleId><ArticleId IdType="pmc">PMC10928099</ArticleId><ArticleId IdType="pubmed">38467657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad W, Ahmad S, Basha R. Analysis of the mutation dynamics of SARS-CoV-2 genome in the samples from Georgia State of the United States. Gene. 2022;841:146774. doi: 10.1016/j.gene.2022.146774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2022.146774</ArticleId><ArticleId IdType="pmc">PMC9323210</ArticleId><ArticleId IdType="pubmed">35905853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>